Skip To Main Content
Louis Fleur on Muck Rack

Louis Fleur

Lyon
As seen in: Complètement Flou, The Lancet
Il est grand temps de se tirer d'ici... @floufleur.bsky.social sur BluSky @floufleur@piaille.fr sur Mastodon @completementflou sur instagram
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Louis

Contact Louis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study - The Lancet Oncology

|
By Louis Fleur, Rob Kessels, Ingrid A Mandjes, Inge Kemper
| The Lancet Verified
1. Gianni L Pienkowski T Im YH et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17: 791-800 2. Broglio KR Quintana M Foster M et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016; 2: 751-760 3.
Open in Who Shared Issue with article?
See all 1 articles